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ORIGINAL ARTICLE
Background/Aims: Recent intravascular ultrasound (IVUS) studies of sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES) have demonstrated a significant reduction in neointimal hyperplasia (NIH) based on simple
coronary lesions. In this study, we evaluated the efficacy of SES and PES using IVUS in complex coronary lesions.
Methods: Eighty-seven patients in whom 95 drug-eluting stents (66 SES and 29 PES) were implanted in
complex coronary lesions were enrolled in this study. Case selection was based on the availability of IVUS and
quantitative coronary angiographic (QCA) examinations at the index procedure and at follow-up. The neointimal
volume index (volume/length: NIVI) and percent neointimal volume (% NIV) were calculated. The longitudinal
length of stented segments without IVUS-detectable NIH was also evaluated.
Results: The baseline patient demographics were similar between the SES and PES groups. At follow-up, no
significant differences were observed in the vessel, plaque, or stent volume indices between the two groups.
However, the NIVI and % NIV were significantly lower in the SES group (p<0.01). The longitudinal length of
stented segments without IVUS-detectable NIH was significantly higher in the SES group (p<0.01). The net gain
was significantly larger in the SES group (2.3±0.7 vs. 2.0×0.6 mm, p=0.025), while the rate of major adverse
cardiac events was similar between the two groups.
Conclusions: Although SES showed significantly greater suppression of NIH at follow-up, both stents were
highly effective at inhibiting NIH in complex coronary lesions. (Korean J Intern Med 2009;24:323-329)
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INTRODUCTION
The introduction of drug-eluting stents (DES) led to a
significant decrease in angiographic and clinical restenosis
by inhibiting smooth muscle cell migration and proliferation
compared with bare-metal stents [1-4]. By demonstrating
differences in the rate of target lesion revascularization
and major adverse cardiac events (MACE), most studies
confirmed the superiority of DES. In addition, a number
of studies indicated that both sirolimus-eluting stents
(SES) and paclitaxel-eluting stents (PES) significantly
decreased the rate of angiographic restenosis despite
differences in late loss [3-6]. However, these studies mostly
focused on simple coronary lesions, although DES tend to
be used in patients with more complex lesions, which are
associated with higher rates of MACE. In addition, in the
evaluation of procedural results, two-dimensional coronary
angiography provides limited information about lesion
characteristics, while intravascular ultrasound (IVUS)
provides unique and more accurate information regarding
neointimal hyperplasia (NIH), vessel remodeling, and stent
apposition [2]. Although a few studies have evaluated theefficacy of DES based on IVUS parameters, IVUS findings
using a 40-MHz transducer with high-quality image
acquisition for complex lesions have not been fully
elucidated. Therefore, the present study was performed to
evaluate and compare NIH between DES in complex
lesions using IVUS with a 40-MHz transducer.
METHODS
Study population and protocol
Eighty-seven patients who had undergone successful
stent implantation with 95 DES and post-stenting IVUS
were enrolled in this study. The SES group consisted of 59
patients with 62 native coronary lesions (66 DES), while
the PES group consisted of 28 patients with 29 native
coronary lesions (29 DES). Signed informed written
consent was obtained from all patients prior to the study.
Patients with signs or symptoms of ischemia who met
the criteria for complex patient characteristics or complex
lesions as follows were enrolled in this study: diabetes,
acute coronary syndrome, lesion types B2 and C according
to the American Heart Association, bifurcation lesions,
recent and chronic total occlusions, ostial lesions, lesions
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Table 1. Baseline clinical and angiographic characteristics
SES PES p value
(n=62) (n=29)
Age, yr 56.9±9.1 58.7±10.4 NS
Male 74.4 82.1 NS
Diabetes mellitus 20.9 17.9 NS
Hypertension 37.2 42.9 NS
Hyperlipidemia 18.6 10.7 NS
Smoking 48.8 28.6 NS
Previous MI 2.3 7.1 NS
Previous PCI 2.3 28.6 0.002
LVEF 55.1±11.8 52.4±10.2 NS
ACS 67.4 64.3 NS
Multi-vessel disease 30.2 28.6 NS
Target vessel 0.004
Left anterior descending artery 72.1 46.4
Left circumflex artery 0 21.4
Right coronary artery 27.9 32.1
Reference vessel diameter, mm 3.3±0.3 3.3±0.5 NS
Lesion length, mm 23.5±9.0 24.4±9.4 NS
Pre-minimal luminal diameter, mm 0.5±0.3 0.5±0.4 NS
Diameter stenosis 84.7±9.4 84.9±11.8 NS
Lesion type NS
A0 0
B1 14.0 14.3
B2 18.6 21.4
C 67.4 64.3
Ostial lesion 12.9 24.1 NS
Bifurcation lesion 14.5 20.7 NS
Left main lesion 8.1 13.8 NS
Chronic total occlusion 12.9 13.8 NS
Stent size, mm 3.3±0.3 3.3±0.5 NS
Stent length, mm 27.0±10.1 26.4±9.0 NS
Maximal inflation pressure, atm  16.4±2.1 14.9±2.2 0.004
Anti-platelet therapy NS
Aspirin/clopidogrel 39.5 57.1
Aspirin/clopidogrel/cilostazol 60.5 42.9
Values are presented as mean±SD or percentages.
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; NS, no significance; MI, myocardial infarction; PCI, percutaneous coronary
intervention; LVEF, left ventricular ejection fraction; ACS, acute coronary syndrome.in the proximal left anterior descending artery, long
lesions (>16 mm), or left main stem lesions. All patients
were older than 18 years and underwent successful stent
implantation with Thrombolysis in Myocardial Infarction
(TIMI) 3 flow. IVUS examination was also performed
after stent deployment at the index procedure, and the
subjects underwent an eight-month IVUS examination as
well as follow-up coronary angiography. Patients were
excluded if they had: 1) intolerance or a contraindication
to aspirin or clopidogrel, 2) advanced heart failure or an
ejection fraction <40%, or 3) severe comorbidity.
All interventions were performed according to current
standard guidelines. When preinterventional IVUS was
performed, stent size was determined according to IVUS
parameters. In cases without preinterventional IVUS,
stent size was determined based on angiographic findings.
When postdilatation was required to optimize stent
expansion or apposition, a balloon shorter than the stent
length was used with careful positioning of the balloon
inside the stent to avoid injury at the edge. Cases in which
incomplete stent apposition (ISA) was not resolved due to
a large proximal reference vessel were classified as acute
ISA. A final IVUS examination was performed after the
last balloon inflation. The patients were premedicated
with aspirin, which was continued indefinitely, and given
clopidogrel (loading dose of 300 mg), which was initiated
24 hours before intervention. The patients were advised to
stay on clopidogrel for ≥6 months after stent deployment.
Quantitative coronary angiographic (QCA)
analysis
The results of coronary angiography, which was
performed according to standard techniques, were
analyzed using a computer-assisted system for QCA
analysis (Digital Cardiac Imaging System; Philips Medical
Systems, Best, The Netherlands) using end-diastolic
frames and a contrast-filled guiding catheter for
calibration. The % diameter stenosis was defined as [1-
(minimal lumen diameter/reference vessel diameter)]
×100. Angiographic restenosis was defined as >50%
diameter stenosis at follow-up. The immediate enlargement
of the luminal diameter produced by stent implantation
(acute gain) and the subsequent reduction in luminal
diameter from the time of intervention to follow-up (late
loss) were calculated. The net gain was thus the sum of the
offsetting effects of acute gain and late loss.
Follow-up evaluation
The baseline clinical characteristics, procedural
characteristics, and clinical outcomes used in this study
were obtained from electronic medical records. Follow-up
angiography was performed after eight to twelve months
with a clinical follow-up of twelve months following stent
implantation. During the follow-up period, MACE, including
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Table 2. Angiographic and clinical results
SES PES p value
(n=62) (n=29)
Post-procedure
Final MLD, mm 3.0±0.3 3.0±0.4 NS
Diameter stenosis 8.8±3.1 9.3±3.9 NS
Follow-up
Final MLD, mm 2.78±0.5 2.5±0.7 0.026
Diameter stenosis 15.1±13.8 21.5±15.9 NS
Acute gain, mm 2.6±0.4 2.5±0.5 NS
Late loss, mm 0.2±0.5 0.5±0.6 0.034
Net gain, mm 2.3±0.7 2.0±0.6 0.025
MACE 1.6 6.9 NS
Death 0 0 NS
MI 0 0 NS
TLR 1.6 3.4 NS
TVR 1.6 6.9 NS
Stent thrombosis 0 3.4 NS
Binary restenosis 0 6.9 NS
Values are presented as mean±SD or percentages.
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; MLD, minimal lumen diameter; NS, no significance; MACE, major adverse cardiac
events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization.cardiac death, non-fatal myocardial infarction, and target
lesion revascularization, were recorded and evaluated.
IVUS imaging protocol
IVUS examinations were performed immediately and
eight to twelve months after stent implantation. All IVUS
images were acquired using a commercially available
ultrasound system (Cardiovascular Imaging System;
Boston Scientific Corp., Natick, MA, USA). A single-
element mechanical transducer (2.5 or 2.9 Fr with a 40-
MHz IVUS catheter; Boston Scientific Corp.) was used.
After the intracoronary administration of 200 µg of
nitroglycerin, the imaging catheter was advanced distal to
the stent and withdrawn with an automated pullback
device at 0.5 mm/second through the stent to the proximal
vessel segment. The ultrasound images were recorded on
a CD for off-line analysis. The IVUS images were analyzed
using commercially available planimetry software
(EchoPlaque; Indec Systems, Santa Clara, CA, USA)
according to previously validated and published protocols
[7]. The lumen, stent, and vessel contours were traced
manually at 1.0-mm axial intervals for both the stented
and reference vessel segments (5-mm segment proximal
or distal to the stent). The plaque area was calculated by
subtracting the lumen area from the vessel area. In the
stented segments, the neointimal contours were also
traced. Simpson’s method was used to calculate the
volumes, which were adjusted by the length. The lumen
volume index (LVI), stent volume index, vessel volume
index (VVI), plaque volume index (PVI), and neointimal
volume index (NIVI) were determined and expressed as
mm
3/mm. The percent neointimal volume (% NIV) was
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Table 4. The Incidence of incomplete stent apposition
SES PES Both p value
(n=62) (n=29) (n=91)
Post-procedure 11 (17.7) 3 (10.3) 14 (15.4) NS
Follow-up 18 (29.0) 4 (13.8) 22 (24.2) NS
Persistent ISA 7 (11.3) 3 (10.3) 10 (11.0) NS
Resolved ISA 4 (6.5) 0 (0.0) 4 (4.4) NS
Late-acquired ISA 11 (17.7) 1 (3.4) 12 (13.2) NS
Values are number (%).
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; ISA, incomplete stent apposition.
Table 3. Serial three-dimensional ultrasound results
SES PES p value† p value‡
(n=62) (n=29)
PS FU p value* PS FU p value*
Proximal reference, mm
3/mm
VVI 17.1±5.7 16.8±4.1 NS 16.0±5.4 16.6±5.4 NS NS NS
LVI 9.3±3.5 9.3±3.1 NS 8.9±3.3 8.8±3.7 NS NS NS
PVI 7.9±3.0 7.4±2.4 NS 7.1±3.0 7.8±3.0 NS NS NS
Stented segment, mm
3/mm
VVI 15.8±3.3 15.9±3.1 NS 16.2±4.4 16.2±4.3 NS NS NS
LVI 7.4±1.1 7.3±1.3 NS 8.3±2.3 7.2±2.3 <0.01 NS NS
PVI 8.4±2.6 8.3±2.1 NS 7.9±2.5 8.0±2.5 NS NS NS
SVI 7.4±1.1 7.5±1.4 NS 8.3±2.3 8.2±2.3 NS NS NS
NIVI 0 0.2±0.4 0.001 0 0.9±0.9 <0.01 NS <0.01
% NIV 0 2.8±4.3 <0.01 0 11.9±10.2 <0.01 NS <0.01
Distal reference, mm
3/mm
VVI 11.9±4.8 12.6±4.3 NS 10.8±4.9 11.5±4.2 NS NS NS
LVI 7.0±2.5 7.6±2.4 NS 6.6±3.0 6.8±2.5 NS NS NS
PVI 5.0±3.1 5.0±2.7 NS 4.1±2.4 4.7±2.6 0.006 NS NS
SES, sirolimus-eluting stents; PES, paclitaxel-eluting stents; PS, post procedure; FU, follow-up; VVI, vessel volume index; LVI, lumen volume
index; PVI, plaque volume index; SVI, stent volume index; NIVI, neointimal volume index; % NIV, percent neointimal volume; NS, no significance.
*p value, post-procedure vs. follow-up.
†p value, SES vs. PES at post-procedure.
‡p value, SES vs. PES at follow-up.calculated as the ratio of the neointimal volume and stent
volume×100. NIVI and % NIV may be used to evaluate
the mean amount of neointima regardless of stent
diameter or length. To examine the distribution pattern of
NIH, the percentage of stent length free from IVUS-
detectable NIH was calculated. The longitudinal length of
stented segments without IVUS-detectable NIH was
determined then divided by the total stented segments in
each case. ISA was defined as one or more struts clearly
separated from the vessel wall with evidence of blood
behind the strut in a segment not associated with any side
branches [8,9]. Resolved ISA was defined as that observed
at baseline but not at follow-up. Persistent ISA was
defined as ISA observed at both baseline and follow-up.
Late-acquired ISA was defined as ISA observed only at
follow-up [10].
Statistical analysis
Statistical analysis was performed using SPSS version
15.0 (SPSS Inc., Chicago, IL, USA). Continuous data are
presented as the mean±standard deviation while categorical
data are presented as the frequency. Continuous variables
were compared by paired or unpaired Student’s t-tests.
Categorical variables were compared by χ
2 and Fisher’s
exact tests. A p<0.05 was considered statistically significant.
RESULTS
Patients and lesion characteristics
A total of 87 patients with 95 drug-eluting stents (SES
group, 59 patients with 66 stents vs. PES group, 28
patients with 29 stents) were enrolled in this study. The
baseline demographic and angiographic data are shown in
Table 1. The baseline characteristics were similar between
the SES and PES groups. The frequency of diabetic
patients was 20.9% in the SES group and 17.9% in the
PES group (p>0.05).
Angiographic and clinical results
Our angiographic and clinical results are listed in Table
2. The mean time to follow-up angiography was 12.5
months. Acute gain was similar between the groups
(2.6±0.4 mm in the SES group vs. 2.5±0.5 mm in the PES
group), while late loss was significantly smaller in the
SES group than in the PES group (0.2±0.5 vs. 0.5±0.6
mm, p=0.034). Thus, net gain was significantly greater in
the SES group (2.3±0.7 vs. 2.0±0.6 mm, respectively;
p=0.025). However, none of the parameters could
independently predict net gain. Differences in the in-
stent restenosis rates between the two groups were not
statistically significant, and there was only one case of
stent thrombosis in the PES group. After one year, there
were no differences in the rate of MACE between the two
groups.
IVUS results
Our serial IVUS data are shown in Table 3. There were
no differences in the baseline IVUS characteristics
between the two groups; however, the NIVI and % NIV in
the stented segment at follow-up were significantly lower
for those lesions treated with SES compared to PES
(0.2±0.4 vs. 0.9±0.9 mm
3/mm, 2.8±4.3 vs. 11.9±10.2%,
respectively; all p<0.01). The LVI at follow-up was
significantly smaller than the postprocedure value in the
PES group (8.3±2.3 mm
3/mm postprocedure vs. 7.2±2.3
mm
3/mm at follow-up, p<0.01). There were no significant
differences in any of the other parameters within the
stented segments. In the proximal and distal reference
segments, the LVI, PVI, and VVI were not significantly
different between the two groups; however, the PVI in the
distal reference segment of the PES group was increased
at follow-up (4.1±2.4 vs. 4.7±2.6 mm
3/mm, p=0.006).
The percentage of stent length free from IVUS-detectable
NIH was significantly longer in the SES group than in the
PES group, indicating that SES had focal NIH while PES
had diffuse NIH (51.1±33.8 vs. 37.1±27.5%, p=0.02).
ISA
ISA was observed in fourteen cases postprocedure and
22 cases at follow-up. Resolved ISA was observed in four
patients (6.5%) in the SES group. Persistent ISA was
observed in seven patients (11.3%) in the SES group and
three patients (10.3%) in the PES group, while late-
acquired ISA was seen in eleven patients (17.7%) in the
SES group and in one patient (3.4%) in the PES group.
However, there was no significant difference in the
incidence rate of ISA between the two groups. ISA at the
index procedure occurred at the proximal edge of the stent
and was related to discrepancies between stent size and
proximal reference vessel size. The location of late-
acquired ISA was at the distal edge in four lesions (33.3%,
four SES) and within the body of the stent in eight lesions
(66.7%, seven SES and one PES). Our results indicate that
the main cause of late-acquired ISA was focal positive
remodeling and not a decrease in plaque volume.
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This study demonstrates the superiority of SES compared
to PES in the suppression of neointimal proliferation,
although both stents were associated with low rates of
binary restenosis and MACE in patients with complex
lesion characteristics [11-17]. Although late loss in our
study appeared to be somewhat higher than that in the
prospectively randomized trial comparing the safety and
efficacy of sirolimus-eluting versus paclitaxel-eluting
coronary stents (REALITY trial) (0.09±0.43 mm in SES
vs. 0.31±0.44 mm in PES, p<0.001) [18], which assessed
the effects of both DES in a head-to-head comparison, the
results were comparable with those in two other studies:
the randomized study of sirolimus- vs. paclitaxel-eluting
stents for coronary revascularization (SIRTAX study) and
a study of paclitaxel- vs. sirolimus-eluting stents for
prevention of restenosis in diabetic patients with coronary
artery disease (ISAR-DIABETES trial) [19,20]. The
difference in late loss might be related to differential
inclusion criteria for the patients, in that patients with
more complex characteristics were enrolled in this study
compared to the REALITY study. There have been few
comparative studies of the efficacy of SES and PES in
reducing NIH by IVUS. The NIH volume in the present
study was 5.8±12.3 mm
3 in the SES group and 23.6±21.0
mm
3 in the PES group (p<0.01). These values correspond
to those from a previous study, which showed a significantly
lower NIH volume in lesions treated with SES compared
to PES. Cervinka et al. [21] reported that SES had a markedly
reduced NIH volume compared to PES based on IVUS
measurements (4.1±11.0 mm
3 in SES vs. 17.4±23.0 mm
3
in PES, p=0.002), however, the amount of NIH was
evaluated based on the total volume regardless of stent
length. In the present study, however, the degree of NIH
was adjusted for the stent length by dividing the NIV by
the stent length to remove any bias caused by differences
in the length of each stent. Petronio et al. [22] also reported
the degree of neointimal proliferation in DES. They
included complex lesions in only the proximal and/or
midportion of the left anterior descending artery and
assessed neointimal proliferation as the NIH area (0.61±
0.41 mm
2 in SES vs. 1.20±0.56 mm
2 in PES, p<0.001),
their results are comparable to those of the present study.
To evaluate the lesions by IVUS, we used a transducer
with a frequency of 40 MHz. Compared to the images
provided by solid-state systems at 20 MHz, those obtained
using a mechanical system at 40 MHz are slightly better,
which may enable a more precise evaluation of neointimal
proliferation.
In most previous studies, determinations of the NIH
pattern were made based on angiographic measurements.
Using this method, it was widely reported that the NIH of
the SES group was of the focal type while that of the PES
group was predominantly of the diffuse type [23,24].
However, coronary angiography provides only indirect
information about restenosis. We evaluated the distribution
of NIH more quantitatively in our study through IVUS;
the portion with or without NIH was validated while the
proportion of stent length free from IVUS-detectable NIH
was calculated as the number of NIH-free frames divided
by the total number of frames. Among the various trials
that have analyzed the efficacy of DES, this is one of the
only studies to provide the NIH pattern through quantifi-
cation by IVUS; our results show a similar NIH distribution
to that reported by Petronio et al. [22] (69.8±29.4 vs.
43.9±34.8%, p<0.001).
The incidence rate of late-acquired ISA in the SES group
was 17.7%, which is similar to the results of previous
studies [25,26]. On the other hand, in the PES group, the
incidence rate of late-acquired ISA was 3.4%, which is
lower than the value reported previously [27]. The lower
incidence in the PES group may be related to the small
number of patients. There were no negative clinical events
after twelve months, similar to other studies [10,26,27].
This study was limited by the small number of patients
enrolled. The sample size was too small to compare the
clinical events, but this was not an endpoint of the present
study. In addition, this was a retrospective and non-
randomized study from a single center. Thus, selection
bias cannot be excluded, and it likely affected the baseline
characteristics. However, such differences had no influence
on the outcomes. Finally, preinterventional IVUS was not
performed in all patients, which may have affected the
determination of the appropriate stent size at the time of
the index procedure.
In summary, compared with PES, SES showed greater
suppression of NIH at follow-up. However, both SES and
PES were highly effective at inhibiting NIH in patients
with complex characteristics, and there were no
significant differences in clinical outcome among the
limited number of cases studied during the relatively short
follow-up period. Additional, large-scale prospective
randomized trials with longer-term IVUS follow-up are
needed to confirm these findings.
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